Traditional Chinese medicine composition for treating emotional diseases

Abstract

The invention relates to a traditional Chinese medicine composition for treating emotional diseases, which consists of active ingredients and pharmaceutically acceptable auxiliary materials, and is characterized in that the active ingredients are prepared from the following raw material medicines in percentage by weight: 15.0 to 18.3 percent of vinegar schisandra chinensis, 11.3 to 13.8 percent of vinegar radix curcumae, 13.1 to 16.0 percent of roasted rhizoma atractylodis macrocephalae, 18.8 to 22.9 percent of poria cocos, 11.3 to 13.8 percent of prepared polygala tenuifolia, 11.3 to 13.8 percent of rhizoma acori graminei roasted with ginger and 9.4 to 11.5 percent of roasted liquorice. All the medicines in the whole formula are compatible and have the effects of dispelling melancholy, soothing the heart, soothing the nerves, invigorating the spleen and replenishing qi.

Description

Field of the Invention

[0001] The invention relates to a medical preparation, in particular to a Chinese medicine composition using plants as raw materials. Background Art

[0002] With the continuous development of modern social economy and the fast-paced life, people are facing fierce social and work competition. These pressures have caused emotional diseases to be ranked as another invisible killer after hypertension and heart disease. According to statistics from the World Health Organization, the prevalence of sleep disorders in my country is as high as 42.7%, and the insomnia rate among middle-aged and elderly people is as high as 60%.

[0003] Emotional disease refers to a disease that is related to emotional stimulation and has abnormal emotional manifestations. It is a type of disease caused by organ dysfunction due to various emotions. Emotional disease includes: (1) diseases caused by emotional stimulation, such as depression, neurosis, anxiety, etc.; (2) diseases induced by emotional stimulation, such as chest pain, true heart pain, dizziness (hypertension) and other physical and mental diseases; (3) diseases caused by other reasons but with abnormal emotional manifestations, such as diabetes, malignant tumors, chronic liver and gallbladder diseases, etc., most of which have abnormal emotional manifestations. Western medicine treatment is mainly symptomatic treatment, and benzodiazepines can be used. Non-benzodiazepines Anti-anxiety drugs such as monoamine oxidase inhibitors, tricyclic antidepressants, sedatives such as trazodone, mirtazapine, doxepin, etc. Modern medicine also focuses on psychotherapy, using psychological intervention, yoga meditation, hyperbaric oxygen stimulation, and enhanced physical exercise.

[0004] Traditional Chinese medicine believes that emotional illness is a disease caused by the internal injury of the seven emotions, which leads to the imbalance of yin and yang, qi and blood in the internal organs. It belongs to the category of "depression syndrome", including mania, palpitations, lily disease, zang-yang agitation, depression syndrome, insomnia, etc. The name of the disease was first seen in the "Classic Classics" by Zhang Jiebin in the Ming Dynasty. The cause of this disease: It is often caused by the deficiency of the body's body and the injury of the seven emotions. The disease is located in the brain, involving the liver, heart, and spleen. Basic pathogenesis: The liver qi is not unblocked, the qi is stagnant, and the depression turns into fire, which consumes yin and blood, and the blood cannot nourish the heart, causing restlessness. Common syndromes: liver depression and qi stagnation syndrome, liver depression and spleen deficiency syndrome, heart and spleen deficiency syndrome, phlegm and qi stagnation syndrome, liver depression and fire syndrome, blood stasis syndrome, phlegm and fire disturbing the heart syndrome, yin deficiency and internal heat syndrome, heart and gallbladder qi deficiency syndrome, kidney essence deficiency syndrome, heart and kidney disharmony syndrome, etc. In terms of treatment, Chinese medicine focuses on syndrome differentiation and treatment, and often uses classic prescriptions and empirical prescriptions, including Xiaoyao Fang, Guipi Fang, Kaixin Powder, Chaihu Shugan Powder, Danzhi Xiaoyao Powder, Huanglian Wendan Decoction, Anshen Dingzhi Pills, etc. At the same time, Chinese medicine auxiliary therapies are widely used: including acupuncture therapy, massage therapy, Chinese medicine emotion therapy, Chinese medicine essential oil therapy, auricular acupoint pressure pills, Baduanjin, music therapy and other therapies.

[0005] Xiaoyao Fang is a classic prescription. The first volume of the 2020 edition of the Chinese Pharmacopoeia contains its pills, water pills, concentrated pills, tablets, capsules, granules and other dosage forms. It is made of eight raw materials, including bupleurum, angelica, white peony root, stir-fried atractylodes, Poria, roasted licorice, mint, ginger, etc. It can soothe the liver and strengthen the spleen, nourish blood and regulate menstruation. It is used for depression, chest and flank pain, dizziness, loss of appetite, and irregular menstruation caused by liver depression and spleen deficiency. Xiaoyao granules are commonly used to treat emotional disorders. However, according to the long-term practice and research of the inventor, the effect of Xiaoyao granules in treating emotional disorders is still not very ideal. Summary of the invention

[0006] The technical problem to be solved by the present invention is to provide a Chinese medicine composition for treating emotional disorders, which has a significant effect in treating emotional disorders.

[0007] The solution of the present invention to solve the above technical problems is:

[0008] A Chinese medicine composition for treating emotional disorders, the Chinese medicine composition is composed of active ingredients and pharmaceutically acceptable excipients, characterized in that the active ingredients are made of the following raw materials in percentage by weight:

[0009] Vinegar Schisandra 15.0-18.3%, vinegar Curcuma 11.3-13.8%, stir-fried Atractylodes 13.1-16.0%, Poria 18.8-22.9%, processed Polygala 11.3-13.8%, ginger-roasted Acorus calamus 11.3-13.8%, and roasted Licorice root 9.4-11.5.

[0010] The Chinese medicine composition of the present invention comprises the following raw materials in an optimal ratio: 16.7% of vinegar schisandra chinensis, 12.5% ​​of vinegar turmeric, 14.6% of stir-fried atractylodes macrocephala, 20.8% of tuckahoe, 12.5% ​​of processed polygala tenuifolia, 12.5% ​​of ginger-fried calamus, and 10.4% of fried liquorice.

[0011] The Chinese medicine composition of the present invention can be prepared by a common method in the art. The method recommended by the present invention is as follows:

[0012] a. Grind the vinegar Schisandrae Chinensis, stir-fried Atractylodes macrocephala and ginger-fried Acorus calamus into coarse powder, add 5 times the volume of 90% ethanol for percolation, collect the percolation liquid, and recover the ethanol until there is no alcohol taste to obtain concentrated percolation liquid; then mix the concentrated percolation liquid with β-CD at a ratio of 8 g β-CD per ml of concentrated percolation liquid, stir at room temperature for 3 hours, filter and vacuum dry to obtain β-CD inclusion compound A; and set aside the residue for use;

[0013] b. Take vinegar turmeric, Poria, processed Polygala and roasted licorice, add appropriate amount of water and soak for 0.5h, add the spare medicinal residue of step a, and boil twice with water; wherein, add 10 times of water for the first time and boil for 2.0h, and add 8 times of water for the second time and boil for 1.0h; combine the two decoctions, filter, concentrate to a relative density of 1.05, and then concentrate to a thick paste with a relative density of 1.30 to 1.35 by tubular centrifugation at a speed of 16000rpm; vacuum dry to obtain dry paste powder B at a temperature of 60°C and a vacuum degree of -0.08Mpa;

[0014] c. Mix the β-CD inclusion compound A and the dry paste powder B, and add appropriate amount of auxiliary materials to prepare the traditional Chinese medicine composition.

[0015] The Chinese medicine composition of the present invention can be various common solid oral preparations, such as granules, tablets or capsules.

[0016] In the raw materials of the present invention, vinegar Schisandra chinensis is the main drug, vinegar Curcuma aromatica and stir-fried Atractylodes macrocephala are the assistant drugs, Poria cocos, processed Polygala tenuifolia, and ginger-fried Acorus calamus are the adjuvant drugs, and stir-fried Licorice root is the guiding drug. Among them, vinegar Schisandra chinensis can replenish the Qi of the five internal organs, is warm in nature, sour in taste, and sour taste enters the liver. At the same time, vinegar enters the liver and enhances the effect on the liver. When matched with stir-fried Licorice root, sour and sweet can transform Yin and replenish liver Yin. Insufficient liver Yin also affects the liver's function of dispersing and discharging. By replenishing liver Yin, the liver's function of dispersing and discharging can be enhanced. In addition, vinegar Schisandra chinensis can replenish Qi and produce body fluid, nourish the kidney and calm the mind, and can calm the mind and stabilize the spirit. Vinegar Curcuma aromatica is cold in nature, bitter and pungent in taste, can promote Qi and relieve depression, clear the heart and cool the blood. Stir-fried Atractylodes macrocephala can invigorate the spleen and replenish Qi. Poria strengthens the spleen, promotes diuresis and eliminates dampness, calms the mind and soothes the nerves. It is combined with stir-fried Atractylodes macrocephala to enhance the function of strengthening the spleen and replenishing qi. By nourishing the spleen and soothing the liver, it helps vinegar Schisandra chinensis and Curcuma aromatica to promote qi and relieve depression, calm the mind and soothe the nerves; processed Polygala tenuifolia calms the nerves and improves intelligence, and communicates the heart and kidneys. Ginger-fried Acorus calamus opens the mind and eliminates phlegm, wakes up the mind and improves intelligence. The two are combined to enhance the function of removing phlegm and opening the mind, calming the nerves and soothing the nerves, and assisting the main medicine to achieve the effect of relieving depression and soothing the nerves, calming the mind and soothing the nerves; roasted Licorice root nourishes the spleen and harmonizes the stomach, replenishes qi and restores the pulse, and harmonizes all the medicines. All the medicines work together to relieve depression, soothe the mind and soothe the nerves, and strengthen the spleen and replenish qi, and can be used for emotional diseases such as qi stagnation, spleen deficiency and liver depression. The Chinese medicine composition of the present invention can be used for emotional diseases such as anxiety, depression, irritability, insomnia and dreaminess, palpitations and forgetfulness, and poor appetite caused by liver depression and spleen deficiency, and the above symptoms are seen.

[0017] The technical effect of the present invention will be further demonstrated through animal experiments.

[0018] 1. Effects on rats with liver depression and spleen deficiency syndrome

[0019] 1 Experimental animals and groups

[0020] Experimental animals: SPF male SD rats (120-150 g) were purchased from the Experimental Animal Center of Southern Medical University, with animal use license number SYXK (Guangdong) 2016-0167 and animal production license number SCXK (Guangdong) 2016-0041. They were kept in the Experimental Animal Center of Southern Medical University at room temperature of 20-25°C, humidity of 30%-40%, artificial light with a 12-h circadian rhythm, and were adaptively raised for 1 week before the experiment.

[0021] 2. Test drugs and administration methods

[0022] The blank control group was fed normally.

[0023] The model group was modeled according to the modeling method.

[0024] Control group: The subjects were given commercially available Xiaoyao granules daily, and the rest was the same as the model group.

[0025] The three drug-administered groups were given the Chinese medicine composition of the present invention by gavage every day, and the rest was the same as the model group. The specific drug-administered groups are as follows:

[0026] Test drug 1: the granules of Example 1 below;

[0027] Test drug 2: the tablet of Example 2 below;

[0028] Test drug 3: the capsule preparation of Example 3 below.

[0029] The above dosages are converted according to human dosages (using the general dosage conversion method, see: Chen Qi. Methodology of Chinese Medicine Pharmacology Research. Beijing: People's Medical Publishing House [M]. 2006: 116) and dissolved in appropriate amount of water for rat gavage.

[0030] 3. Animal model making

[0031] Rat chronic mild unpredictable stress (CUMS) model: Except for the blank control group, rats were subjected to CUMS combined with solitary housing to establish a depression model. During this period, rats were required to receive different stress stimuli, including water deprivation for 24 hours, food deprivation for 24 hours, swimming in 4°C ice water for 5 minutes, tail clamping for 1 minute, electric shock to the sole of the foot (voltage 50mV, stimulation once every 5s, interval 5s, total stimulation 10 times), day and night reversal, shaking (1 time / s, lasting 5min). One stimulus was randomly selected every day, and no two were repeated. The modeling time was 3 weeks in total, and the normal control group was free to eat during this period. After the modeling was completed, the depression model was evaluated by behavior, and the rats with successful modeling were randomly divided into groups according to the behavioral performance. They were divided into model group, control group, test drug group 1, test drug group 2, and test drug group 3, with 10 rats in each group, and the drug was administered by gavage for 2 weeks.

[0032] The positive control group was given Xiaoyao granules [0.9g / (kg·d)], and the three experimental groups were given 0.90g / (kg·d) once a day for 21 consecutive days. The normal group and the model group rats were gavaged with the same volume of 0.9% sodium chloride solution. After 3 weeks, 1ml injection (sodium pentobarbital with a concentration of 4.5mg·ml-1) was given to each 100g rat for intraperitoneal anesthesia and samples were collected. Blood was collected from the abdominal aorta, centrifuged at 4℃ to obtain serum, and the animals were killed. The spleen, thymus, and small intestine tissues of the rats were taken and frozen at -80℃ for later use.

[0033] 4 Test methods:

[0034] 4.1 General characterization observations

[0035] Before and after modeling in the morning of each day, the animals' mental state, restraint reaction, feces texture, fur, auricle, palpebral fissure mucosa color and other external manifestations were observed with the naked eye. The results are shown in Table 1.

[0036] Table 1 Changes in the appearance of rats in each group before and after the experiment

[0037]

[0038] The results showed that after modeling, the rats showed obvious appearance characteristics different from those of the blank control group. The rats were listless, with dry, loose and dull hair, reduced activity, reduced stimulus response, soft stool, loose stool, easy to contaminate bedding, etc. After the control drug Xiaoyao granules and the sample of the present invention were given, the appearance characteristics of the model group were significantly improved in all aspects, but the mental state of the Xiaoyao granules control group was slightly worse, indicating that the sample of the present invention has more obvious effects in relieving depression and calming the mind and improving sleep.

[0039] 4.2 Determination of organ / body weight ratio

[0040] At the end of the experiment, spleen, thymus and small intestine tissues of rats were taken and weighed on an electronic analytical balance to calculate the organ / body ratio (mg / g). The results are shown in Table 2.

[0041] Table 2 Changes in organ / body ratio and body weight of rats in each group after the experiment ( n=10)

[0042]

[0043] *P<0.05, comparison between each group and the model group; #P<0.05, comparison between the test sample group and the control group.

[0044] The results showed that compared with the blank control group, the rats showed a more obvious weight loss after modeling; after administration of the control drug Xiaoyao Granules and the sample of the present invention, compared with the model group, the weight gain of the control drug Xiaoyao Granules and the sample of the present invention was significantly accelerated (P<0.05), and the ratio of each organ / body was significantly increased (P<0.05). The control drug Xiaoyao Granules and the sample of the present invention can significantly improve the body weight, digestive tissue and immune tissue function of CUMS rats. At the same time, the various indicators of the sample of the present invention are better than those of the control drug Xiaoyao Granule as a whole, and some indicators are significantly improved (P<0.05), indicating that the sample of the present invention has a more obvious effect of relieving depression and strengthening the spleen.

[0045] 4.3 Small Intestinal Propulsion Rate Test

[0046] 30 minutes before anesthesia, rats in each group were gavaged with 0.4 mL of 2% dextran blue-2000 (DB-2000). The propulsion distance of DB-2000 in the small intestine and the total length of the small intestine were measured. The propulsion rate of DB-2000 in the small intestine of rats was calculated according to the formula: small intestine propulsion rate = DB-2000 intestinal propulsion distance (cm) / small intestine total length (cm) × 100%. The results are shown in Table 3.

[0047] The results showed that compared with the blank control group, the propulsion rate in the small intestine of the rats after modeling was significantly reduced; after administration of the control drug Xiaoyao Granules and the sample of the present invention, compared with the model group, the small intestinal propulsion rate of the sample of the present invention was significantly increased (P<0.05), and the control drug Xiaoyao Granules was increased, indicating that the control drug Xiaoyao Granules and the sample of the present invention can increase the small intestinal propulsion rate of CUMS rats. At the same time, the sample of the present invention is better than the control drug Xiaoyao Granules as a whole, indicating that the spleen-strengthening effect of the sample of the present invention is more obvious.

[0048] 4.5 Sugar water preference test

[0049] The core symptom of depression is anhedonia, and sugar water consumption is an effective indicator of animal anhedonia. Rats were deprived of water but not food for 24 hours before the test. During the test, all rats were given 1 bottle of pure water and 1 bottle of 1% sucrose water for a sugar water consumption test. The consumption was weighed 1 hour later, and the sugar water consumption ratio was calculated as shown in the following formula. Sugar water preference tests were performed on days 0, 7, 14, and 21 of the test. The results are shown in Table 3.

[0050] Sugar water preference rate = sucrose water consumption / (sucrose water consumption + pure water consumption) × 100%

[0051] The results showed that compared with the blank control group, the sugar water preference rate of rats after modeling was significantly reduced; after administration of the control drug Xiaoyao Granules and the samples of the present invention, compared with the model group, the sugar water preference rate of the control drug Xiaoyao Granules and the samples of the present invention was significantly increased (P<0.05), indicating that the control drug Xiaoyao Granules and the samples of the present invention can increase the sugar water preference rate of CUMS rats. At the same time, the various indicators of the samples of the present invention are better than those of the control drug Xiaoyao Granules as a whole, and the test samples 1-3 are significantly improved (P<0.05), indicating that the depression-relieving effect of the samples of the present invention is more obvious.

[0052] 4.4 Open field test

[0053] The open field test uses the animal's adaptability and exploratory ability to a new environment to evaluate its behavioral state. The test was conducted in a separate room and kept quiet. At 8:00 a.m. on the 21st day, the open field test was conducted. The test device was a test box with multiple square grids on the bottom. The camera installed on the top of the device was adjusted to aim at the bottom of the box. The rats' activities in the open field box within 5 minutes were observed, and the following indicators were analyzed and recorded: total activity distance, number of times crossing the center, and rest time. After a single test, wipe the bottom of the box with alcohol, and conduct the next test after the smell has dissipated. The results are shown in Table 3.

[0054] Table 3 Results of small intestinal propulsion rate test, sugar water preference test, and open field test ( n=10)

[0055]

[0056] *P<0.05, comparison between each group and the model group; #P<0.05, comparison between the test sample group and the control group.

[0057] The results showed that compared with the blank control group, all indicators of the open field test of the rats after modeling showed obvious changes, the movement distance was significantly shortened, the number of crossing the central area was significantly reduced, and the stationary time was significantly prolonged (P<0.05); after the control drug Xiaoyao granules and the sample of the present invention were administered, compared with the model group, all indicators of the open field test of the control drug Xiaoyao granules and the sample of the present invention showed obvious changes, the movement distance was significantly increased (P<0.05), the number of crossing the central area was significantly increased (P<0.05), and the stationary time was significantly reduced (P<0.05), indicating that the control drug Xiaoyao granules and the sample of the present invention can improve all indicators of the open field test of CUMS rats, and at the same time, all indicators of the sample of the present invention are better than those of the control drug Xiaoyao granules as a whole, and the movement distance of the test samples 1-3 is significantly increased (P<0.05), indicating that the depression-relieving effect of the sample of the present invention is more obvious.

[0058] 4.6 Effects of neurotransmitters on HPA function in the hypothalamus-pituitary-adrenal axis

[0059] ELISA method was used to detect the levels of corticotropin-releasing hormone CRH, adrenocorticotropic hormone ACTH, cortisol CORT, 5-hydroxytryptamine 5-HT, norepinephrine NE, and dopamine DA in rat serum. The levels of CRH, ACTH, CORT, 5-HT, NE, and DA in rat serum were detected according to the instructions of the ELISA kit. The results are shown in Table 4.

[0060] Table 4 CRH, ACTH, CORT, 5-HT, NE, DA levels in serum of rats in each group after the experiment (ng / ml, n=10)

[0061]

[0062]

[0063] *P<0.05, comparison between each group and the model group; #P<0.05, comparison between the test sample group and the control group.

[0064] The results showed that compared with the blank control group, the various indicators of HPA functional neurotransmitters in the serum of rats after modeling showed obvious changes, and CRH, ACTH, CORT, 5-HT, NE, and DA were all significantly increased (P<0.05); after administration of the control drug Xiaoyao Granules and the sample of the present invention, compared with the model group, the various indicators of HPA functional neurotransmitters in CUMS rats of the control drug Xiaoyao Granules and the sample of the present invention showed obvious changes, and CRH, ACTH, CORT, 5-HT, NE, and DA were all significantly reduced (P<0.05), indicating that the control drug Xiaoyao Granules and the sample of the present invention can improve the various indicators of HPA functional neurotransmitters in CUMS rats. At the same time, the various indicators of the sample of the present invention are better than those of the control drug Xiaoyao Granule as a whole. The ACTH of test samples 1-3 and test sample 2, and the 5-HT of test sample 1 are significantly lower (P<0.05), indicating that the depression-relieving effect of the sample of the present invention is more obvious.

[0065] It can be seen from the above that the medicine described in the present invention can improve the appearance of CUMS rats, improve their mental state, increase their activity, and reduce loose stools; it can significantly improve the weight, digestive tissue and immune tissue function of CUMS rats; increase the small intestinal propulsion rate of CUMS rats; increase the sugar water preference rate of CUMS rats; improve the various indicators of the open field test of CUMS rats, increase the movement distance, increase the number of times crossing the central area, and reduce the static time; it can significantly reduce the HPA functional neurotransmitters CRH, ACTH, CORT, 5-HT, NE, DA, etc. of CUMS rats. This shows that the medicine of the present invention has good effects of relieving depression, soothing the mind, and strengthening the spleen and replenishing qi. At the same time, the various indicators of the medicine of the present invention are better than Xiaoyao granules, which shows that the medicine of the present invention has a unique therapeutic effect for the treatment of anxiety, depression, irritability, insomnia, dreaminess, palpitations, forgetfulness, poor appetite and other emotional diseases caused by liver depression and spleen deficiency syndrome, and the above symptoms, which also shows that the medicine of the present invention is reasonable. DETAILED DESCRIPTION

[0066] Example 1

[0067] 1. Prescription: Vinegar Schisandra 8.0g, Vinegar Curcuma 6.0g, Stir-fried Atractylodes 7.0g, Poria 10.0g, Processed Polygala 6.0g, Roasted Acorus calamus with ginger 6.0g, Roasted Licorice 5.0g.

[0068] 2. Preparation method:

[0069] a. Grind the vinegar Schisandrae Chinensis, stir-fried Atractylodes macrocephala and ginger-fried Acorus calamus into coarse powder, add 5 times the volume of 90% ethanol for percolation, collect the percolation liquid, and recover the ethanol until there is no alcohol taste to obtain concentrated percolation liquid; then mix the concentrated percolation liquid with β-CD at a ratio of 8 g β-CD per ml of concentrated percolation liquid, stir at room temperature for 3 hours, filter and vacuum dry to obtain β-CD inclusion compound A; and set aside the residue for use;

[0070] b. Take vinegar turmeric, Poria, processed Polygala and roasted licorice, add appropriate amount of water and soak for 0.5h, add the spare medicinal residue of step a, and boil twice with water; wherein, add 10 times of water for the first time and boil for 2.0h, and add 8 times of water for the second time and boil for 1.0h; combine the two decoctions, filter, concentrate to a relative density of 1.05, and then concentrate to a thick paste with a relative density of 1.30 to 1.35 by tubular centrifugation at a speed of 16000rpm; vacuum dry to obtain dry paste powder B at a temperature of 60°C and a vacuum degree of -0.08Mpa;

[0071] c. Mix the β-CD inclusion compound A and the dry paste powder B, add an appropriate amount of dextrin, mix well, granulate with 90% ethanol, dry, granulate, and bag to prepare granules.

[0072] 3. Dosage: Oral, 5g at a time, twice a day.

[0073] Example 2

[0074] 1. Prescription: 8.8g of Schisandra chinensis with vinegar, 6.3g of Curcuma aromatica with vinegar, 7.0g of stir-fried Atractylodes macrocephala, 9.0g of Poria cocos, 5.7g of processed Polygala tenuifolia, 6.0g of roasted Acorus calamus with ginger, and 5.2g of roasted Licorice root.

[0075] 2. Preparation method:

[0076] a. Grind the vinegar Schisandrae Chinensis, stir-fried Atractylodes macrocephala and ginger-fried Acorus calamus into coarse powder, add 5 times the volume of 90% ethanol for percolation, collect the percolation liquid, and recover the ethanol until there is no alcohol taste to obtain concentrated percolation liquid; then mix the concentrated percolation liquid with β-CD at a ratio of 8 g β-CD per ml of concentrated percolation liquid, stir at room temperature for 3 hours, filter and vacuum dry to obtain β-CD inclusion compound A; and set aside the residue for use;

[0077] b. Take vinegar turmeric, Poria, processed Polygala and roasted licorice, add appropriate amount of water and soak for 0.5h, add the spare medicinal residue of step a, and boil twice with water; wherein, add 10 times of water for the first time and boil for 2.0h, and add 8 times of water for the second time and boil for 1.0h; combine the two decoctions, filter, concentrate to a relative density of 1.05, and then concentrate to a thick paste with a relative density of 1.30 to 1.35 by tubular centrifugation at a speed of 16000rpm; vacuum dry to obtain dry paste powder B at a temperature of 60°C and a vacuum degree of -0.08Mpa;

[0078] c. Mix the β-CD inclusion compound A and the dry paste powder B, granulate with 90% ethanol, dry, add 0.5% magnesium stearate by weight of the granules, mix, press, and film-coat to prepare tablets.

[0079] 3. Dosage: Orally, 5 tablets at a time, twice a day.

[0080] Example 3

[0081] 1. Prescription: Vinegar Schisandra 7.2g, vinegar Curcuma 5.7g, stir-fried Atractylodes 7.3g, Poria 10.8g, processed Polygala 6.3g, ginger-roasted Acorus calamus 6.0g, and roasted Licorice root 4.7g.

[0082] 2. Preparation method:

[0083] a. Grind the vinegar Schisandrae Chinensis, stir-fried Atractylodes macrocephala and ginger-fried Acorus calamus into coarse powder, add 5 times the volume of 90% ethanol for percolation, collect the percolation liquid, and recover the ethanol until there is no alcohol taste to obtain concentrated percolation liquid; then mix the concentrated percolation liquid with β-CD at a ratio of 8 g β-CD per ml of concentrated percolation liquid, stir at room temperature for 3 hours, filter and vacuum dry to obtain β-CD inclusion compound A; and set aside the residue for use;

[0084] b. Take vinegar turmeric, Poria, processed Polygala and roasted licorice, add appropriate amount of water and soak for 0.5h, add the spare medicinal residue of step a, and boil twice with water; wherein, add 10 times of water for the first time and boil for 2.0h, and add 8 times of water for the second time and boil for 1.0h; combine the two decoctions, filter, concentrate to a relative density of 1.05, and then concentrate to a thick paste with a relative density of 1.30 to 1.35 by tubular centrifugation at a speed of 16000rpm; vacuum dry to obtain dry paste powder B at a temperature of 60°C and a vacuum degree of -0.08Mpa;

[0085] c. Mix the β-CD inclusion compound A and the dry paste powder B, and pack them into capsules to prepare capsules.

[0086] 3. Dosage: Orally, 5 tablets at a time, twice a day.

[0087] The above examples 1-3 all use commercially available vinegar Schisandra chinensis, vinegar Curcuma aromatica, stir-fried Atractylodes macrocephala, processed Polygala tenuifolia, ginger-fried Acorus calamus and roasted Licorice root as medicines, but it is obvious that a person skilled in the art can also prepare them by themselves according to the following method:

[0088] Preparation method of vinegar schisandra: take clean schisandra, add 20% vinegar, mix well and simmer for a while, put in a steaming container, simmer for 3 hours over low heat until the vinegar is absorbed and the surface turns black purple, take out and dry to obtain vinegar schisandra;

[0089] Preparation method of stir-fried Atractylodes macrocephala: take 10% of the amount of the medicinal material, roasted bran with honey, pour it into a stir-frying container until it smokes, add Atractylodes macrocephala slices and stir-fry until yellow-brown and emit a burnt aroma, sieve out the honey bran and let it cool to get the stir-fried Atractylodes macrocephala;

[0090] The preparation method of ginger-fried Acorus calamus is as follows: take 12.5% ​​of the medicinal material amount of ginger slices, decoct according to the decoction decoction method (add water to cover the medicinal surface, decoct twice, the first decoction is 30 minutes, the second decoction is 20 minutes, filter and combine the filtrate) to prepare ginger juice, pour it into the Acorus calamus slices, mix well, moisten thoroughly, put it in a pot, and fry it with a slow fire until it is dry, so as to obtain ginger-fried Acorus calamus;

[0091] Preparation method of vinegar turmeric: take clean turmeric, add 10% vinegar, mix well and moisten, put into a preheated frying container, heat with slow fire, fry until dry, take out, and let cool to get vinegar turmeric;

[0092] Processing method of processed Polygala: take 6% licorice, decoct according to the decoction method (add water to cover the medicinal surface, decoct twice, the first decoction is 30 minutes, the second decoction is 20 minutes, filter and combine the filtrate) to prepare licorice decoction, add clean Polygala, add clean Polygala, cook with slow fire until the licorice decoction is absorbed, take out, dry, and obtain processed Polygala;

[0093] Preparation method of roasted licorice: take 25% of the medicinal material with refined honey, add the same amount of boiling water to dilute it, add clean licorice slices, mix well and moisten it, put it in a preheated frying container, heat it over low heat, fry until it turns yellow to dark yellow, take it out when it is no longer sticky, and let it cool.

Claims

1. A Chinese medicine composition for treating emotional disorders, the Chinese medicine composition comprising active ingredients and pharmaceutically acceptable excipients, characterized in that: The active ingredient is made of the following raw materials in percentage by weight: Vinegar Schisandra 15.0-18.3%, vinegar Curcuma 11.3-13.8%, stir-fried Atractylodes 13.1-16.0%, Poria 18.8-22.9%, processed Polygala 11.3-13.8%, ginger-roasted Acorus calamus 11.3-13.8%, and roasted Licorice root 9.4-11.5%.

2. A Chinese medicine composition for treating emotional disorders according to claim 1, characterized in that: The active ingredients are prepared from the following raw materials in percentage by weight: 16.7% of vinegar schisandra, 12.5% ​​of vinegar turmeric, 14.6% of stir-fried atractylodes, 20.8% of tuckahoe, 12.5% ​​of processed polygala, 12.5% ​​of ginger-fried calamus, and 10.4% of fried liquorice.

3. A Chinese medicine composition for treating emotional disorders according to claim 1 or 2, characterized in that: The Chinese medicine composition is prepared by the following method: a. Grind the vinegar Schisandrae Chinensis, stir-fried Atractylodes macrocephala and ginger-fried Acorus calamus into coarse powder, add 5 times the volume of 90% ethanol for percolation, collect the percolation liquid, and recover the ethanol until there is no alcohol taste to obtain concentrated percolation liquid; then mix the concentrated percolation liquid with β-CD at a ratio of 8 g β-CD per ml of concentrated percolation liquid, stir at room temperature for 3 hours, filter and vacuum dry to obtain β-CD inclusion compound A; and set aside the residue for use; b. Take vinegar turmeric, Poria, processed Polygala and roasted licorice, add appropriate amount of water and soak for 0.5h, add the spare medicinal residue of step a, and boil twice with water; wherein, add 10 times of water for the first time and boil for 2.0h, and add 8 times of water for the second time and boil for 1.0h; combine the two decoctions, filter, concentrate to a relative density of 1.05, and then concentrate to a thick paste with a relative density of 1.30 to 1.35 by tubular centrifugation at a speed of 16000rpm; vacuum dry to obtain dry paste powder B at a temperature of 60°C and a vacuum degree of -0.08Mpa; c. Mix the β-CD inclusion compound A and the dry paste powder B, and add appropriate amount of auxiliary materials to prepare the traditional Chinese medicine composition.

4. A Chinese medicine composition for treating emotional disorders according to claim 1 or 2, characterized in that: The traditional Chinese medicine composition is in the form of granules, tablets or capsules.

Images